🔗 Permalink

Inventor profile of:

Dimiter S. Dimitrov

City:

Frederick, Maryland

Country:

United States

Published Applications:

Last publication date:

2024-09-19

Top Assignees for applications by Dimiter S. Dimitrov

The entities that hold a legal rights for patent applications filed by inventor Dimitrov Dimiter S.:

The USA, as represented by the Secretary, Department of Health and Human Services 23 Bethesda, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 18 Washington, DC United States
LENTIGEN TECHNOLOGY, INC. 17 Gaithersburg, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 16 Bethesda, MD United States
The United States of America as represented by the Secretary of the Department of Health and Human Services 7 Washington, DC United States
Memorial Sloan-Kettering Cancer Center 7 New York, NY United States
The United States of America,as represented by the Secretary,Department of Health and Human Services 5 Bethesda, MD United States
BIOMED VALLEY DISCOVERIES, INC. 5 Kansas City, MO United States
PURDUE RESEARCH FOUNDATION 4 West Lafayette, IN United States
The United States of America, as represented by the Secretary, Dept. of Health & Human Services 2 Bethesda, MD United States
The United States of America as Represented by the Department of Health and Human Services 2 Washington, DC United States
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF 2 BETHESDA, MD United States
The United States of America, as Represented by the Secretary, Dep. of Health and Human Services 2 Bethesda, MD United States
The United States of America as represented by the Secretary, Department of Health and Human Service 2 Bethesda, MD United States
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY 2 Hong Kong, China
The United States of America, as represented by the Secretary, Department of Health and Human Serv 2 Bethesda, MD United States
The Scripps Research Institute 1 La Jolla, CA United States
The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services 1 Bethesda, MD United States
The United States of America, as Presented by the Secretary, Department of Health and Human Services 1 Bethesda, MD United States
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH.... 1 Bethesda, MD United States
Government of the United States of America 1 Rockville, MD United States
The Government of the United States of America, as represented by the Secretary 1 Rockville, MD United States
The United States of America, as represented by the Secretary, Department of Heath and Human Services 1 Bethesda, MD United States
United States of America as Represented by the Secretary, The Dept. of Health and Human Services 1 Bethesda, MD United States
Veritech Limited 1 Hong Kong, Hong Kong
The United States of America, as represented by the Secretary, Department of Health and Human 1 Bethesda, MD United States
The Government of the United States America as represented by the Secretary of the Department of Health and Human Services 1 Bethesda, MD United States
THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH 1 ROCKVILLE, MD United States
The United States of America as Represented by the Secretary of the Army 1 Washington, DC United States
Services 1 Rockville, MD United States
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI 1 Rockville, MD United States
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HE 1 Rockville, MD United States
GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT 1 Rockville, MD United States
The United States of America, as Represented by the Secretary, Dept. of Health and Human Resources 1 Bethesda, MD United States
The Gov of USA, as Represented by the Secretary, Dept. of Health and Human Services 1 Rockville, MD United States
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE 1 BETHESDA, MD United States
The United States of America, as represented by the Secretary, Dept. of Health & Human Services 1 Rockville, MD United States
The United States of America, as represent by the Secretary, Department of Health and Human Services 1 Washington, DC United States
Department of Health and Human Service 1 Besthesda, MD United States
The Children's Hospital of Philadelphia 1 Philadelphia, PA United States
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services 1 Bethesda, MD United States
RESEARCH CORPORATION TECHNOLOGIES, INC. 1 Tucson, AZ United States
FUDAN UNIVERSITY 1 Shanghai, China
The United States of America,as represented by the Secretary, Department of Health and Human Service 1 Bethesda, MD United States
THE UNITED STATES OF AMERICA DEPEARTMENT OF HEALTH AND HUMAN SERVICES 1 Washington, DC United States

Recent patent applications by Dimitrov Dimiter S.

Dimiter S. Dimitrov from Frederick, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-09-19

US20240309102A1

Chemistry; metallurgy

Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy

#2 | 2024-09-05

US20240294639A1

Chemistry; metallurgy

ANTIGEN-BINDING PROTEINS TARGETING CD56 AND METHODS OF PRODUCING THEREOF

#3 | 2024-04-04

US20240108706A1

Human necessities

Compositions and Methods for Treating Cancer with Anti-CD22 Immunotherapy

#4 | 2024-03-14

US20240084008A1

Chemistry; metallurgy

M971 CHIMERIC ANTIGEN RECEPTORS

#5 | 2024-03-14

US20240084007A1

Chemistry; metallurgy

M971 CHIMERIC ANTIGEN RECEPTORS

#6 | 2024-02-29

US20240067724A1

Chemistry; metallurgy

Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy

#7 | 2023-10-05

US20230312706A1

Chemistry; metallurgy

USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS

#8 | 2023-08-03

US20230241103A1

Human necessities

Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy

#9 | 2023-04-13

US20230110875A1

Chemistry; metallurgy

ANTI-CD276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS

#10 | 2022-12-08

US20220389094A1

Chemistry; metallurgy

Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy

#11 | 2021-11-18

US20210353675A1

Human necessities

Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy

#12 | 2021-06-10

US20210171645A1

Chemistry; metallurgy

Human monoclonal antibodies against EphA4 and their use

#13 | 2021-05-06

US20210130479A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-CD123 immunotherapy

#14 | 2020-10-15

US20200325223A1

Chemistry; metallurgy

Methods of treatments using antigen-binding proteins targeting CD56

#15 | 2020-09-10

US20200283522A1

Chemistry; metallurgy

M971 chimeric antigen receptors

#16 | 2020-08-13

US20200255534A1

Chemistry; metallurgy

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

#17 | 2020-07-30

US20200239569A1

Chemistry; metallurgy

Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors

#18 | 2020-07-23

US20200231663A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

#19 | 2020-06-25

US20200199246A1

Chemistry; metallurgy

Anti-CD276 antibodies (B7H3)

#20 | 2020-06-25

US20200197440A1

Human necessities

Compositions and methods for treating cancer with anti-CD38 immunotherapy

#21 | 2020-05-21

US20200155661A1

Human necessities

Compositions and methods for treating cancer with anti-CD22 immunotherapy

#22 | 2020-04-23

US20200123254A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-CD19 immunotherapy

#23 | 2020-04-02

US20200102385A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

#24 | 2020-04-02

US20200101109A1

Human necessities

Compositions and methods for treating cancer with anti-CD33 immunotherapy

#25 | 2020-01-09

US20200010555A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-CD123 immunotherapy

#26 | 2019-11-21

US20190352408A1

Chemistry; metallurgy

Human monoclonal antibodies specific for FLT3 and uses thereof

#27 | 2019-07-18

US20190218280A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

#28 | 2019-04-11

US20190106492A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-CD19 immunotherapy

#29 | 2019-04-04

US20190099476A1

Human necessities

Compositions and methods for treating cancer with anti-CD22 immunotherapy

#30 | 2019-03-21

US20190085078A1

Chemistry; metallurgy

M971 chimeric antigen receptors

#31 | 2019-02-21

US20190055309A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

#32 | 2018-11-08

US20180318440A1

Human necessities

Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use

#33 | 2018-10-04

US20180280438A1

Human necessities

Compositions and methods for treating cancer with anti-CD33 immunotherapy

#34 | 2018-09-06

US20180251546A1

Chemistry; metallurgy

Mesothelin-targeted chimeric antigen receptors and methods of making them

#35 | 2018-09-06

US20180251544A1

Chemistry; metallurgy

ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND METHODS OF USE

#36 | 2018-08-16

US20180230214A1

Chemistry; metallurgy

Antigen-binding proteins targeting CD56 and uses thereof

#37 | 2018-08-02

US20180214568A1

Human necessities

Antibody-drug conjugates for targeting CD56-positive tumors

#38 | 2018-07-26

US20180208645A1

Chemistry; metallurgy

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

#39 | 2018-07-05

US20180186890A1

Chemistry; metallurgy

Anti-CD276 antibodies (B7H3)

#40 | 2018-05-17

US20180134800A1

Chemistry; metallurgy

Human monoclonal antibodies specific for glypican-3 and use thereof

#41 | 2018-05-03

US20180118815A1

Chemistry; metallurgy

Bispecific multivalent fusion proteins

#42 | 2018-03-29

US20180086812A1

Chemistry; metallurgy

Stabilized single human CD4 domains and fusion proteins

#43 | 2017-12-28

US20170369585A1

Chemistry; metallurgy

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

#44 | 2017-08-31

US20170247453A1

Chemistry; metallurgy

Soluble engineered monomeric Fc

#45 | 2017-08-03

US20170218075A1

Chemistry; metallurgy

Human monoclonal antibodies against EPHA4 and their use

#46 | 2017-08-03

US20170218052A1

Chemistry; metallurgy

CROSS-REACTIVE ANTIBODIES AGAINST DENGUE VIRUS AND USES THEREOF

#47 | 2017-05-25

US20170145097A1

Chemistry; metallurgy

Human monoclonal antibodies specific for CD22

#48 | 2017-03-23

US20170081405A1

Chemistry; metallurgy

Mesothelin-targeted chimeric antigen receptors and uses thereof

#49 | 2017-03-23

US20170081393A1

Chemistry; metallurgy

Engineered antibody constant domain molecules

#50 | 2016-09-15

US20160264647A1

Chemistry; metallurgy

Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides

#51 | 2016-07-21

US20160208015A1

Chemistry; metallurgy

Human monoclonal antibodies specific for glypican-3 and use thereof

#52 | 2016-07-21

US20160207999A1

Chemistry; metallurgy

Anti-human folate receptor beta antibodies and methods of use

#53 | 2016-07-21

US20160207985A1

Chemistry; metallurgy

Anti-HIV domain antibodies and method of making and using same

#54 | 2016-05-26

US20160145338A1

Chemistry; metallurgy

Human monoclonal antibodies specific for CD22

#55 | 2016-05-12

US20160130359A1

Chemistry; metallurgy

HER2-specific monoclonal antibodies and conjugates thereof

#56 | 2016-02-25

US20160053017A1

Chemistry; metallurgy

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

#57 | 2016-02-11

US20160039904A1

Chemistry; metallurgy

STABILIZED SINGLE HUMAN CD4 DOMAINS AND FUSION PROTEINS

#58 | 2016-01-28

US20160024199A1

Chemistry; metallurgy

Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

#59 | 2015-10-22

US20150299317A1

Chemistry; metallurgy

M971 chimeric antigen receptors

#60 | 2015-10-01

US20150274836A1

Chemistry; metallurgy

Mesothelin antibodies and methods for eliciting potent antitumor activity

#61 | 2015-09-03

US20150246967A1

Chemistry; metallurgy

Human domain antibodies against components of the human insulin-like growth factor (IGF) system

#62 | 2015-08-06

US20150218255A1

Chemistry; metallurgy

Cross-reactive antibodies against dengue virus and uses thereof

#63 | 2015-07-23

US20150202284A1

Human necessities

METHOD OF MAKING A VACCINE

#64 | 2015-04-23

US20150110798A1

Chemistry; metallurgy

Anti-human folate receptor beta antibodies and methods of use

#65 | 2015-02-19

US20150050278A1

Chemistry; metallurgy

Soluble engineered monomeric Fc

#66 | 2014-09-18

US20140271646A1

Chemistry; metallurgy

Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)

#67 | 2014-02-13

US20140044720A1

Chemistry; metallurgy

Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

#68 | 2014-02-13

US20140044714A1

Chemistry; metallurgy

Human monoclonal antibodies specific for glypican-3 and use thereof

#69 | 2014-01-23

US20140023645A1

Chemistry; metallurgy

Engineered antibody constant domain molecules

#70 | 2013-11-28

US20130315921A1

Chemistry; metallurgy

Human monoclonal antibodies specific for CD22

#71 | 2013-07-25

US20130189247A1

Chemistry; metallurgy

Multimeric Proteins Comprising Immunoglobulin Constant Domains

#72 | 2013-07-11

US20130177570A1

Chemistry; metallurgy

Anti-human folate receptor beta antibodies and methods of use

#73 | 2013-05-02

US20130108636A1

Chemistry; metallurgy

High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins

#74 | 2012-08-02

US20120195897A1

Chemistry; metallurgy

Human domain antibodies against components of the human insulin-like growth factor (IGF) system

#75 | 2012-05-10

US20120114656A1

Chemistry; metallurgy

Human monoclonal antibodies protective against bubonic plague

#76 | 2011-05-05

US20110104163A1

Chemistry; metallurgy

Anti-HIV domain antibodies and method of making and using same

#77 | 2011-01-27

US20110020361A1

Chemistry; metallurgy

Human anti-mesothelin monoclonal antibodies

#78 | 2011-01-27

US20110020344A1

Chemistry; metallurgy

Human monoclonal antibodies specific for CD22

#79 | 2011-01-13

US20110008358A1

Chemistry; metallurgy

Human monoclonal antibodies that specifically bind IGF-II

#80 | 2010-12-16

US20100317837A1

Chemistry; metallurgy

IDENTIFICATION OF NOVEL BROADLY CROSS-REACTIVE NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES USING SEQUENTIAL ANTIGEN PANNING OF PHAGE DISPLAY LIBRARIES

#81 | 2010-12-16

US20100316641A1

Chemistry; metallurgy

Engineered antibody constant domain molecules

#82 | 2010-03-04

US20100055033A1

Chemistry; metallurgy

Human monoclonal antibodies that bind human insulin like growth factors and their use

#83 | 2009-12-10

US20090304683A1

Chemistry; metallurgy

Soluble Fragments of The Sars-Cov Spike Glycoprotein

#84 | 2009-11-26

US20090291493A1

Human necessities

Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency

#85 | 2008-08-14

US20080193465A1

Physics

Human monoclonal antibodies that specifically bind IGF-II

#86 | 2008-02-14

US20080038280A1

Chemistry; metallurgy

A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines

#87 | 2007-12-20

US20070292390A1

Chemistry; metallurgy

Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies

#88 | 2007-09-13

US20070212363A1

Human necessities

Immunoglobulins with Potent and Broad Antiviral Activity

#89 | 2007-09-13

US20070212349A1

Chemistry; metallurgy

Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes

#90 | 2006-10-26

US20060240515A1

Chemistry; metallurgy

Soluble fragments of the SARS-CoV spike glycoprotein

InventorID:

221962 ⎘